699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy

BackgroundAnti-PD-1 therapy is the mainstay of frontline treatment for NSCLC and melanoma. However, the majority of these patients become refractory/resistant. BV is hypothesized to selectively deplete a subset of activated effector intratumoral regulatory T-cells (Tregs) that express CD30, potentia...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2023-11, Vol.11 (Suppl 1), p.A794-A794
Main Authors: Lee, Sylvia, Jotte, Robert M, Gillespie-Twardy, Amanda, Mehmi, Inderjit, Chandra, Sunandana, Zakharia, Yousef, Hamid, Omid, Watson, Graham, Ward, Patrick, Chaney, Marya, Lu, Hailing, Berndt, Jason D, Rathi, Kapil, Knowles, Scott, O’Connor, Brian P, Cowey, Charles
Format: Article
Language:English
Subjects:
Biopsy
Cancer
Immunotherapy
Lung cancer
Melanoma
Metastasis
Regular and Young Investigator Award Abstracts
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundAnti-PD-1 therapy is the mainstay of frontline treatment for NSCLC and melanoma. However, the majority of these patients become refractory/resistant. BV is hypothesized to selectively deplete a subset of activated effector intratumoral regulatory T-cells (Tregs) that express CD30, potentially re-sensitizing tumors to anti-PD-1 therapy. SGN35–033 (NCT04609566) is an ongoing, multi-cohort, multicenter, open-label trial evaluating the efficacy and safety of BV+pembro in anti-PD-1 refractory solid tumors.MethodsPatients with primary refractory (progression without response or SD for
ISSN:2051-1426
DOI:10.1136/jitc-2023-SITC2023.0699